Loading patent…
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsPeter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
Estimating the term…
The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
A method of treating an infectious or inflammatory disorder comprising administering, to a subject in need of such treatment, an effective amount of isopropyl 3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxyhexopyranoside that reduces one or more sign or symptom of inflammation in the subject.
A method of treating a disease or disorder involving TLR4activation comprising, administering to a subject in need of such treatment, an effective amount of isopropyl 3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxyhexopyranoside that reduces one or more sign or symptom of inflammation in the subject.
A pharmaceutical composition comprising isopropyl 3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxyhexopyranoside.
Dependencies are inferred from the claim text.